Dubois Josée, Thomas-Chaussé Frédéric, Soulez Gilles
CHU Sainte-Justine, Montreal, Canada.
CHU Sainte-Justine, Montreal, Canada.
Tech Vasc Interv Radiol. 2019 Dec;22(4):100631. doi: 10.1016/j.tvir.2019.100631. Epub 2019 Sep 23.
The approach to treating common (cystic) lymphatic malformations (LMs) has evolved significantly over the last decade due to clinical research and recent developments in molecular biology. Surgery, sclerosing agents, and medical drugs with specific targets for biological therapy have been reported for the management of LMs. We will discuss the importance to standardize the location and imaging characterization of LMs to improve the knowledge about the outcome of the different therapeutic options. Our goal is to help the reader understand the different options for the management of LMs with the balance between risk and benefit for the patients.
在过去十年中,由于临床研究和分子生物学的最新进展,常见(囊性)淋巴管畸形(LMs)的治疗方法有了显著发展。手术、硬化剂以及具有生物治疗特定靶点的药物已被报道用于LMs的管理。我们将讨论标准化LMs的定位和影像学特征描述的重要性,以增进对不同治疗选择结果的了解。我们的目标是帮助读者了解LMs管理的不同选择,以及患者风险与获益之间的平衡。